Teva Launches Generic Version of Tarceva in US
09 Mai 2019 - 11:31PM
Dow Jones News
By Stephen Nakrosis
Teva Pharmaceutical Industries Ltd. (TEVA) said Thursday it was
launching a generic version of Tarceva, or erlotinib, tablets in
the U.S.
Erlotinib tablets are a kinase inhibitor indicated for the
treatment of certain patients with metastatic non-small cell lung
cancer, Teva said. Erlotinib tablets are also indicated for
first-line treatment of certain patients with pancreatic
cancer.
Tarceva is distributed in the U.S. by Astellas Pharma U.S. in
partnership with Genentech, a member of The Roche Group.
--Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
May 09, 2019 17:16 ET (21:16 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Teva Pharmaceutical Indu... (NYSE:TEVA)
Graphique Historique de l'Action
De Juil 2024 à Août 2024
Teva Pharmaceutical Indu... (NYSE:TEVA)
Graphique Historique de l'Action
De Août 2023 à Août 2024
